

Wayne A. Solley, M.D.

Vitreoretinal Specialist

Postgraduate Training

- Fellow, Vitreoretinal Disease and Surgery
Emory Eye Center, Atlanta, Georgia
Chairman: Thomas Aaberg, Sr., MD
- Chief Resident, Ophthalmology
Emory Eye Center, Atlanta, Georgia
Chairman: Thomas Aaberg, Sr., MD
- Resident, Ophthalmology
Emory Eye Center, Atlanta, Georgia
Chairman: Thomas Aaberg, Sr., MD
- Transitional Internship
The Baptist Medical Centers
Birmingham, Alabama
Chairman: Joe Bancroft, MD

Education

- The University of Iowa College of Medicine
M.D. conferred May 1993, with Honors
Iowa City, Iowa
- Louisiana Tech University
B.S., Zoology, conferred May 1989
summa cum laude

Honors and Awards

- Chief Resident in Ophthalmology, 1996-1997
- Alpha Omega Alpha Junior Year Inductee, 1992, Treasurer, 1992-1993
- Gross Human Anatomy Prosector, 1990
- Mortar Board, President, 1989
- Omicron Delta Kappa Honor Society, 1989
- Outstanding Entering Zoology Student Award, 1985
- Outstanding Freshman Zoology Student Award, 1986
- Monsanto Corporation National Merit Scholarship, 1985-1989
- Virginia Cage Memorial Award, 1989

Activities and Employment

- Emergency Technician, Rapides General Hospital, Alexandria, Louisiana, 1990
- Research and Development Team, Cargill, Inc, Eddyville, Iowa, 1989
- Laboratory Instructor, Freshman/Sophomore Zoology, 1989
- Sigma Nu Social Fraternity, 1985-1989, Academic Chairman, 1988
- Campus Intramural Golf Champion, Louisiana Tech University, 1987-1989
- Louisiana Tech Varsity Golf Team, 1985-1986
- National PGA Junior Golf Tournament finalist, 1985

Certification and Licensure

- Diplomate, American Board of Ophthalmology, May 16, 1999
- Texas licensure, April 10, 1999 to present (License#K7398)
- Ophthalmology Written Qualifying Examination (WQE), Passed, 1998
- Federal Licensure Examination (FLEX), Passed, 1992
- Licensed in State of Georgia, October 6, 1994-present
- DEA Certification

Professional Associations

- American Academy of Ophthalmology
- American Medical Association
- Alpha Omega Alpha
- Tarrant County Medical Society
- Tarrant County Ophthalmological Society
- Texas Medical Association
- Vitreous Society

Presentations

- Solley WA, Capone AC "Telemedicine Diabetic Eye Screening in an Urban African-American Population"; Residents' Day, June 7, 1997, Atlanta, Georgia.
- Solley WA, Martin D, Newman N, et al. Cat Scratch Disease Posterior Segment Manifestations; Poster presented at American Academy of Ophthalmology Annual Meeting, San Francisco, California, October 1997.
- Solley WA, Martin D, Newman N, et al. "Posterior Segment Manifestations of Cat Scratch Disease"; Residents' Day, June 5, 1996, Atlanta, Georgia.

Research and Publications

- Solley, WA, Martin D, Newman N, et al. Cat Scratch Disease: Posterior Segment Manifestations. *Ophthalmology* 1999; 106:1546-1553
- Solley WA, Sternberg PS. Retinal Phototoxicity. In: *International Ophthalmology Clinics*. Friedlaender MH, ed; Lippincott-Rave, 1999(accepted for publication)
- Segal WA, Solley WA, Sternberg PS, Capone AC. Refractive Outcome Following Unilateral Retinopexy in Infants with Asymmetric Retinopathy of Prematurity. *Progress in Retinopathy of Prematurity*, pp. 179-181, Kugler Publications, 1997 (Proceedings of the International Symposium on Retinopathy of Prematurity, Taormina, Italy, September 21-24, 1997)
- Solley WA, Taub L: Subconjunctival Abscess Caused by Haemophilus Influenzae. (submitted)
- Solley WA, Broocker G: The General Eye Exam. In: *Ophthalmology for the Primary Care Physician*; Palay DA, Krachmer JH, eds, Mosby, 1997.
- Solley WA, Broocker G: Ocular Trauma. In: *Ophthalmology for the Primary Care Physician*, Palay DA, Krachmer JH, eds; Mosby, 1997.
- Solley WA, Kardon R, Thompson HS. Relative Contributions of the Nasal and Temporal Fields in Normal Eyes; Comparison of Visual and Pupillomotor Input. Research at the University of Iowa Department of Ophthalmology; August 1992-May

1993.

Clinical Trials

- Ophthalmic Consultant: TAP Pharmaceutical Products, Inc. Protocol M98-946 Investigational Drug Study for Overactive Bladder, June 2000
- Ophthalmic Consultant: TAP Pharmaceutical Products, Inc. Protocol TAK 637-99-101 Investigational Drug Study for Overactive Bladder, 52-Week Extension Study, September 2000
- Principal Investigator: Genentech Protocol FVF 2128G, A Phase I/II Multicenter Dose Escalation Controlled Study of the Safety, Tolerability, and Pharmacokinetics, and the Activity of Multiple Dose Intravitreal Injections of Rhu-FAB V2 in Subjects with Neovascular Age-Related Macular Degeneration; Genentech, San Francisco, CA; 7/2001
- Sub-investigator: Bausch and Lomb Protocol BLP 415-001, A Multicenter, Randomized, Double-Masked Controlled Study to Evaluate the Safety and Efficacy of an Intravitreal Fluocinolone Acetonide (0.5 or 2.0 mg) Implant in Patients with Non-infectious Uveitis Affecting the Posterior Segment of the Eye; Bausch and Lomb Pharmaceuticals, Tampa, FL, 10/2000
- Sub-Investigator: Control Delivery Systems Protocol CDS FL-002, A Multicenter, Randomized, Masked, Controlled Study to Evaluate the Safety and Efficacy of an Intravitreal Fluocinolone (0.6, or 2.1 mg) Implant in Patients with Diabetic Macular Edema; Control Delivery Systems, Inc., Watertown, MA, 10/2000
- Sub-Investigator: Control Delivery Systems Protocol CDS FL-005, A Multicenter, Randomized, Masked, Controlled Study to Evaluate the Safety and Efficacy of an Intravitreal Fluocinolone Implant in Patients with Diabetic Macular Edema; Control Delivery Systems, Inc., Watertown, MA, 10/2000
- Sub-Investigator: VAM Protocol No. BPD OPCR 005. An Open-Label Multicenter Safety Study of the Treatment of Predominantly Classic Subfoveal Choroidal Neovascularization (CNV) Secondary to Age Related Macular Degeneration (AMD) Using Photodynamic Treatment with Verteporfin for Injection. Verteporfin in AMD Study.
- Sub-Investigator: Eyetech Protocol EOP1004, Phase II-III Randomized Double-Masked Controlled Dose-Ranging Multicenter Comparative Trial in Parallel Groups to Establish the Safety and Efficacy of Intravitreal Injections of Eye001 (Anti-VEGF Pegylated Aptamer) Given Every Six Weeks for Fifty-Four Weeks, in Patients with Exudative Macular Degeneration.

Lectures

- "Idiopathic Macular Holes," Vitreoretinal Disease Update, Presbyterian Hospital of Dallas, Dallas, Texas, 5/2001
- "Retina Look-Alikes," Vitreoretinal Disease Update, Presbyterian Hospital of Dallas, Dallas, Texas, 5/2001
- "Age-Related Eye Disease," Arlington Memorial Hospital Community Fair, Arlington, Texas, 2/2000
- "Ocular Trauma," Vitreoretinal Disease Update, Presbyterian Hospital of Dallas, Dallas, Texas, 10/1999
- "Retinal Detachment and Diabetic Retinopathy: Evaluation and Treatment," Tarrant County Optometric Society Annual Meeting, Fort Worth, Texas, 2000

